Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)Renato Bassan, Alessandro Rambaldi, Arianna Masciulli et al.|Blood|2016Cited by 22
Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06Chiara Caprioli, Alessandro Rambaldi, Giacomo Gianfaldoni et al.|Haematologica|2020Cited by 22
High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG)Silvia Salmoiraghi, Orietta Spinelli, Roberta Cavagna et al.|Cancers|2020Cited by 10
Identification of a Chromatin-Splicing Mutational Signature to Define Secondary Acute Myeloid Leukemia: A Report from the Northern Italy Leukemia Group (NILG) Prospective Trial 02/06Chiara Caprioli, Alessandro Rambaldi, Federico Lussana et al.|Blood|2019Cited by 1
Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06Chiara Caprioli, Federico Lussana, Tamara Intermesoli et al.|Blood|2018Cited by 0